PT  - JOURNAL ARTICLE
AU  - Ganesh, Ravindra
AU  - Pawlowski, Colin
AU  - O’Horo, John C.
AU  - Arndt, Lori L.
AU  - Arndt, Richard
AU  - Bell, Sarah J.
AU  - Bierle, Dennis M.
AU  - Borgen, Molly Destro
AU  - Hanson, Sara N.
AU  - Heyliger, Alexander
AU  - Larsen, Jennifer J.
AU  - Lenehan, Patrick
AU  - Orenstein, Robert
AU  - Puranik, Arjun
AU  - Speicher, Leigh L.
AU  - Tulledge-Scheitel, Sidna M.
AU  - Venkatakrishnan, AJ
AU  - Wilker, Caroline G.
AU  - Badley, Andrew D.
AU  - Razonable, Raymund R.
TI  - Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19
AID  - 10.1101/2021.05.23.21257670
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.23.21257670
4099  - http://medrxiv.org/content/early/2021/05/25/2021.05.23.21257670.short
4100  - http://medrxiv.org/content/early/2021/05/25/2021.05.23.21257670.full
AB  - Background Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed.Methods 2,335 patients who received single-dose bamlanivimab infusion between November 12, 2020 to February 17, 2021 were compared with a propensity-matched control of 2,335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states. The primary outcome was the rate of hospitalization at days 14, 21 and 28.Results The median age of the population was 63; 47.3% of the bamlanivimab-treated cohort were ≥65 years; 49.3% were female. High-risk characteristics included hypertension (54.2%), body mass index ≥35 (32.4%), diabetes mellitus (26.5%), chronic lung disease (25.1%), malignancy (16.6%), and renal disease (14.5%). Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs 3.5%; Odds Ratio [OR], 0.38), 21 (1.9% vs 3.9%; OR, 0.46), and 28 (2.5% vs 3.9%; OR, 0.61). Secondary exploratory outcomes included lower intensive care unit admission rates at days 14 (0.14% vs 1%; OR, 0.12), 21 (0.25% vs 1%; OR: 0.24) and 28 (0.56% vs 1.1%; OR: 0.52), and lower all-cause mortality at days 14 (0% vs 0.33%), 21 (0.05% vs 0.4%; OR,0.08) and 28 (0.11% vs 0.44%; OR, 0.01). Adverse events were uncommon with bamlanivimab, occurring in 19/2355, most commonly fever (n=6), nausea (n=5), and lightheadedness (n=3).Conclusions Among high-risk patients with mild to moderate COVID-19, treatment with bamlanivimab was associated with a statistically significant lower rate of hospitalization compared with usual care.Funding Mayo Clinic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded by intramural grant from Mayo Clinic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mayo Clinic IRB# 20-012919All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in the manuscript is maintained by the authors and available upon request